Unlocking the true power of PET
A powerful new platform to diagnose, study, and treat disease
Radiopharmaceuticals for the modern world
We are working to improve the scope, safety, use, and cost of PET imaging.
PET scans are critical for detecting and diagnosing disease in clinical settings, but their true potential remains largely untapped.
A single, disease-agnostic platform that scales
We make it possible to rapidly produce a broad range of fluorine-18 radiopharmaceuticals based on a single, catalyst-driven, disease-agnostic chemistry platform.
Our patented HetSiFA™ compositions, synthesized using our alkali metal catalysts, can attach to disease-targeting ligands at record-breaking speed.
Other features of our platform further simplify and shorten the radiopharmaceutical manufacturing process. Our chemistry can occur at room temperature, in aqueous solution, without metallic additives, and with no HPLC purification.Learn More
Solving for existing challenges
Accelerating drug discovery
Valuable from the earliest stages of drug discovery, PET imaging of new drug candidates provides unique pharmacokinetic information and quantification of drug properties in vivo. Our radiolabeling platform can make PET a ubiquitous, essential, and cost-effective tool that improves decision-making and increases returns on R&D investment throughout all stages of the drug development process.
We apply Fuzionaire’s core chemistry, based on alkali metal catalysts, to make new radiotracers.Read More
Get in touch
If you are interested in learning more about our radiolabeling platform, we want to hear from you.Contact